HS-20117 combined with aumolertinib for advanced EGFR‑mutant non-squamous lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter Phase Ib/III study of HS-20117, a fully human EGFR‑MET IgG1‑like bispecific antibody, given with the EGFR tyrosine kinase inhibitor aumolertinib in patients with locally advanced or metastatic non‑squamous NSCLC harboring EGFR sensitizing mutations (Exon 19 deletions or Exon 21 L858R). Phase Ib uses a dose‑expansion design to characterize safety, tolerability, pharmacokinetics, immunogenicity, and to determine the recommended Phase III dose. After dose confirmation, a randomized, open‑label Phase III portion will compare HS-20117 plus aumolertinib versus aumolertinib alone to measure efficacy and safety outcomes. The study enrolls adults with measurable disease and ECOG 0–1 at participating cancer centers in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or females aged 18 - 75 years (inclusive).
* Participants with newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic EGFR-sensitive mutated NSCLC (stage IIIB/IIIC/IV) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.
* Agree to provide fresh or archival tumor tissue.
* At least one target lesion per the RECIST v1.1.
* ECOG performance status of 0-1.
* Minimum life expectancy \> 12 weeks.
* Males or Females should be using adequate contraceptive measures throughout the study.
* Females must not be pregnant at screening or have evidence of non-childbearing potential.
* Have signed Informed Consent Form.

Exclusion Criteria:

* Received or are receiving the following treatments:

  1. Previous or current treatment with MET targeted therapy or EGFR targeted antibodies or antibody-drug conjugates (ADC).
  2. Traditional Chinese medicine indicated for tumors, major surgery or other local therapy within washout period to the first dose of study drug.
  3. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
  4. Other investigational non-anti-tumor drugs, strong CYP3A4 inhibitors, strong inducers, drugs that are sensitive substrates of BCRP or P-gp, or drugs that prolong the QT interval within the washout period.
* Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
* History of other primary malignancies.
* Untreated, or active central nervous system metastases.
* Inadequate bone marrow reserve or organ functions.
* Severe, uncontrolled or active cardiovascular disorders.
* Severe or uncontrolled systemic diseases.
* Severe bleeding symptoms or bleeding tendencies.
* Severe arteriovenous thrombosis occurred.
* Serious or active infection.
* Active infectious diseases.
* Interstitial lung disease (ILD).
* Serious neurological or mental disorders.
* History of hypersensitivity to any component of HS-20117 and Aumolertinib or their similar drugs.
* Female subjects who are pregnant, lactating, or planning to become pregnant or breastfeed during the study period or within 6 months after the last dose of the study drug.
* Subjects with a history of severe allergic reactions or those who have experienced severe infusion reactions
* Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin Municipality, China Recruiting
• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Dingzhi Huang, M.D. — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: Jialei Fu
• Email: fujl@hspharm.com
• Phone: +86 18652105685

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Aglatimagene Besadenovec with Prodrug and Pembrolizumab vs Docetaxel for Advanced Non-Squamous NSCLC

  This phase 3 trial tests whether giving aglatimagene besadenovec with a prodrug and pembrolizumab works better than standard chemotherapy (docetaxel) for adults with stage IV non-squamous NSCLC that progressed on pembrolizumab.

  Recruiting Phase 3 Candel Therapeutics, Inc. · New York, New York · NCT07660094

• Aumolertinib with phased chemotherapy for EGFR L858R lung cancer that has spread

  This trial tests whether adding phased chemotherapy to aumolertinib helps people with EGFR L858R–positive metastatic lung adenocarcinoma.

  Recruiting Phase 2 Taipei Medical University Hospital · New Taipei City and 2 other locations · NCT07624487

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

  This treatment combines BL-M07D1 with pembrolizumab to see if it helps people with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07264816

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.